கல்லீரல் இதழ்

சுருக்கம்

Complete Response of Hepatocellular Carcinoma to Sorafenib: A Case Report and Review of Literatures

Lian-yu Chen, Kun Wang and Zhen Chen

Background: Sorafenib is the current standard treatment for advanced and unresectable hepatocellular carcinoma (HCC). Although the efficacy of sorafenib on the overall survival and time to progression has been repeatedly proven, clinically evident and sustainable response especially Complete Response (CR) is rarely observed after its treatment.

Case Report: We report a case of a 64-year old female patient with unresectable HCC who received sorafenib treatment of more than 8 months following a Transarterial Chemoembolization (TACE) treatment. The patient had a rapid and complete response within 1 month of sorafenib treatment, which sustained for more than 7 months after the initiation of the therapy.

Conclusions: This result suggests that sorafenib alone or its use with TACE may be useful in the treatment of unresectable HCC. Translational clinical trials are needed to identify and exploit the underlying mechanism for this superb but rare observation.